Hematopoietic stem cell transplantation in multiple myeloma

Area of Science:

• Hematology
• Oncology
• Stem Cell Transplantation

Background:

• High-dose therapy and autologous hematopoietic stem cell transplantation (HSCT) are standard early treatments for multiple myeloma.
• Tandem transplantation shows promise, especially for patients with suboptimal initial responses.
• Myeloablative allogeneic transplantation offers a potential cure but is limited by high mortality.

Purpose of the Study:

• To critically evaluate the evolving role of hematopoietic stem cell transplantation in multiple myeloma management.
• To assess the impact of newer induction regimens and risk-adapted stratification on transplantation outcomes.
• To analyze the comparative benefits and risks of autologous versus allogeneic HSCT in multiple myeloma.

Main Methods:

• Review of current literature and clinical data on HSCT in multiple myeloma.
• Analysis of outcomes based on transplantation type (autologous, tandem, allogeneic).
• Evaluation of induction regimens and risk stratification strategies.

Main Results:

• Autologous HSCT and tandem transplantation are established early treatments with varying efficacy.
• Allogeneic HSCT, despite curative potential, remains associated with significant treatment-related mortality.
• Advancements in induction therapies and risk stratification are influencing HSCT decision-making.

Conclusions:

• Hematopoietic stem cell transplantation remains a cornerstone in multiple myeloma treatment, with autologous approaches being standard.
• Tandem autologous transplantation may enhance outcomes in select patient groups.
• Further research and risk-adapted strategies are crucial for optimizing the use of allogeneic HSCT and improving overall survival in multiple myeloma.